IPA, Natco withdraw opposition to Gilead’s drug

Indian Pharmaceutical Alliance (IPA) withdrew its opposition to the patent application for Gilead Pharmasset’s Hepatitis C drug sofosbuvir, marketed as Sovaldi, after the latter entered into a voluntary licensing agreement with 11 companies to sell the generic version at a lower price.

#GileadPharmassetsHepatitisCdrugsofosbuvir #IndianPharmaceuticalAlliance #IPA #Sovaldi